Albany, NY -- (SBWIRE) -- 10/02/2012 -- This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine market place.Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient population—the field of stratified medicine.

Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report we describe the current state of the marketplace from the following perspectives:

All the Prognostic and Predictive Biomarkers with Potential Clinical Utility are described—a few have already been developed into CDx and we expect growth in this space
Targeted Therapeutics, Associated Biomarkers, Therapeutic Indications, and Testing Mandates are Described
Companion Diagnostics Partnerships and Collaborations from 2009 to 2012 are Presented—Provides an Up-to-Date State of the Industry Describing the Disease Areas being Addressed and Types of Biomarkers Being Deployed
Quantitative Market Metrics
Quantitative Market Forecast: Market Sizing and Growth Rate
Revenue Breakout: Rx versus Dx
Targeted Rx and CDx Pricing
Publication Hotspot Analyses of the Various Cancer Biomarker Classes for Identifying Niches of Market Opportunity in Various Disease Classes
This data-driven characterization of the Companion Diagnostics and Personalized Medicine field is a hands-on document that can be used for competitive benchmarking, business planning, and strategy development—all the data that have been collected in this industry analysis are presented and they form the basis for the conclusions drawn throughout the market report presented in a format enabling “drag-and-drop” into business presentations/business plans—this Market Report is written and delivered to customers in PowerPoint format.

Browse All Reports of Pharmaceutical Market Research Reports

Extensive Market Analyses Presented in this Report

Personalized Medicine and Companion Diagnostics: Market Segmentation and Quantitative Analysis

Prognostic Biomarkers in Cancer Listing, Description, and Clinical Significance
Predictive Biomarkers in Cancer Listing, Description, and Clinical Significance
Summary of Pathways to Regulatory Approval of Companion Diagnostics
LDTs under CLIA Certification
Outcomes with Drugs in Various Disease Classes
Percent of Tumor Classes where Tumors are Associated with Characterized Somatic Mutations
Companion Diagnostics and Personalized Medicine: Quantitative Market Metrics
How Much Does it Cost to Develop a Companion Diagnostic?
Precedent for Premium Pricing in Cancer Targeted Therapeutics
Pricing of Selected Personalized Medicine Tests
Growth of the Personalized Medicine Marketplace: Market Size/Forecast and Growth Rate
Personalized Medicine Industry Landscape: Selected Indications, Biomarkers and Therapeutics

Market Trends and Evolution of the CDx Marketplace

Disparities between Rx and CDx Companies
Varying Economic Incentives between Rx and Dx Development
Increasing Targeted Rx in the Oncology Space and Effect on CDx Development
Current Rx/CDx Co-development Programs in Phase III Trials with Listing of Associated Biomarkers
Cancer Classes Addressable by CDx
Characterization of Molecular Biomarker Classes: Hotspot Analysis of Publications
Cancer Biomarkers
Oncogenes
Tumor Suppressor Genes
Non-coding RNAs
Collaborations and Partnering in the CDx Space

2012
2011
2010
2009

Browse Full Report with TOC : http://www.researchmoz.us/companion-diagnostics-and-personalized-medicine-market-report-2012-report.html